Logos Global Management LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001792126

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidHealth TiltHigh Turnover how tags are computed

Q3 2026 · 64 positions · Total reported value $1.66B · Top-10 concentration 47.8% · Updated 2026-11-16

Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR

Turnover: 75.9% · 15 new · 29 cut · 19 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.7% · Prev Value $2.32B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -8.1% · vs SPY -10.3% · Latest Value $1.66B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, Logos Global Management LP disclosed 64 equity positions with a combined reported value of $1.66B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 47.8% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were PRAX ($123.77M), RVMD ($123.16M), IDYA ($109.50M). By sector, the heaviest allocations are Health Care 98.5%, Industrials 0.4%. Versus the prior quarter, allocation shifted away from Health Care (-0.6pp).

Versus the prior quarter, Logos Global Management LP opened 15 new positions, trimmed 29 and fully exited 19, a turnover rate of 75.9% of positions. The portfolio's overlap with the prior quarter was 59% of names.

The largest new positions opened in Q3 2026 were MDGL ($50.40M), NBIX ($35.46M), AXSM ($32.27M).

Of the 19 positions fully exited versus the prior quarter, the largest were CLDX ($78.14M), MLYS ($28.33M), XENE ($27.16M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • MDGL MADRIGAL PHARMACEUTICALS INC · $50.40M
  • NBIX NEUROCRINE BIOSCIENCES INC · $35.46M
  • AXSM AXSOME THERAPEUTICS INC. · $32.27M
  • DARE YARROW BIOSCIENCE INC · $23.11M
  • SRPT SAREPTA THERAPEUTICS INC · $18.22M
  • BHVN BIOHAVEN LTD · $13.35M
  • ENTX ENTERA BIO LTD · $12.84M
  • GRTX ELECTRA THERAPEUTICS INC · $11.25M

Fully Exited (vs previous quarter)

  • CLDX CELLDEX THERAPEUTICS INC NEW · prev qtr: $78.14M
  • MLYS MINERALYS THERAPEUTICS INC · prev qtr: $28.33M
  • XENE XENON PHARMACEUTICALS INC · prev qtr: $27.16M
  • FTH FAETH THERAPEUTICS INC · prev qtr: $18.05M
  • DBVT DBV TECHNOLOGIES S A · prev qtr: $15.01M
  • RYTM RHYTHM PHARMACEUTICALS INC · prev qtr: $13.88M
  • VOR VOR BIOPHARMA INC · prev qtr: $11.97M
  • SRRK SCHOLAR ROCK HLDG CORP · prev qtr: $11.00M

Insider Transactions (Form 4)

Latest Logos Global Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Logos Global Management LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 68 US equity positions with a combined value of $2.32B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: SAN FRANCISCO, CA, United States
  • SEC registration: 801-117248 (status: Approved), registered 2019-08-26
  • Regulatory AUM (Form ADV): $2.25B as of 2026-04-22
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 5 private funds, of which 1 hedge funds

Portfolio Structure

  • 68 positions · $2.32B reported value (Q2 2026)
  • Top 10 holdings = 48.3% of reported value
  • Largest position: ERAS (ERASCA INC COM) at 9.6%
  • Average position size: $34.16M

Sector Tilt

  • Health Care 99.1%
  • Financials 0.1%
  • (classified holdings cover 99% of value)

Quarterly Activity

  • Q2 2026: 25 new, 18 added, 19 reduced, 20 exited
  • 6 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 98.5%
Financials 0.2%
Other 0.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 425.00K $123.77M 7.44%
7.44%
Add
2 600.00K $123.16M 7.40%
7.40%
Reduce
3 2.85M $109.50M 6.58%
6.58%
Reduce
4 870.00K $86.15M 5.18%
5.18%
Reduce
5 975.00K $69.12M 4.16%
4.16%
Reduce
6 1.01M $66.44M 3.99%
3.99%
Add
7 650.00K $63.90M 3.84%
3.84%
Reduce
8 2.15M $53.64M 3.23%
3.23%
Reduce
9 100.00K $50.40M 3.03%
3.03%
New
10 1.08M $49.51M 2.98%
2.98%
Add
11 3.00M $48.33M 2.91%
2.91%
Add
12 6.00M $46.02M 2.77%
2.77%
Add
13 500.00K $44.02M 2.65%
2.65%
Reduce
14 1.35M $40.88M 2.46%
2.46%
Add
15 1.25M $40.02M 2.41%
2.41%
Add
16 2.50M $36.65M 2.20%
2.20%
Reduce
17 250.00K $35.46M 2.13%
2.13%
New
18 200.00K $33.96M 2.04%
2.04%
Reduce
19 175.00K $32.27M 1.94%
1.94%
New
20 1.00M $31.27M 1.88%
1.88%
Add
21 3.21M $27.72M 1.67%
1.67%
Hold
22 935.00K $25.41M 1.53%
1.53%
Reduce
23 750.00K $24.22M 1.46%
1.46%
Add
24 1.03M $23.11M 1.39%
1.39%
New
25 1.50M $23.00M 1.38%
1.38%
Add
26 1.45M $20.69M 1.24%
1.24%
Reduce
27 170.00K $20.61M 1.24%
1.24%
Reduce
28 1.50M $19.86M 1.19%
1.19%
Reduce
29 600.00K $19.37M 1.17%
1.17%
Reduce
30 1.00M $18.22M 1.09%
1.09%
New
31 1.50M $17.55M 1.05%
1.05%
Reduce
32 1.00M $16.91M 1.02%
1.02%
Reduce
33 500.00K $15.14M 0.91%
0.91%
Reduce
34 250.00K $13.83M 0.83%
0.83%
Reduce
35 1.00M $13.35M 0.80%
0.80%
New
36 350.00K $13.32M 0.80%
0.80%
Add
37 500.00K $12.91M 0.78%
0.78%
Reduce
38 4.41M $12.84M 0.77%
0.77%
New
39 1.00M $12.57M 0.76%
0.76%
Reduce
40 1.00M $12.44M 0.75%
0.75%
Reduce
41 850.00K $12.40M 0.75%
0.75%
Reduce
42 1.00M $11.25M 0.68%
0.68%
New
43 3.29M $11.02M 0.66%
0.66%
Hold
44 250.00K $9.60M 0.58%
0.58%
Reduce
45 1.00M $8.09M 0.49%
0.49%
Reduce
46 1.00M $7.39M 0.44%
0.44%
New
47 2.00M $7.38M 0.44%
0.44%
New
48 2.00M $6.54M 0.39%
0.39%
New
49 200.00K $6.52M 0.39%
0.39%
New
50 2.22M $5.71M 0.34%
0.34%
Hold

FAQ

What did Logos Global Management LP buy in 2026-Q3?

In its 2026-Q3 13F filing, Logos Global Management LP reported 64 equity positions worth $1.66B in aggregate; its largest disclosed positions were PRAX ($123.77M), RVMD ($123.16M), IDYA ($109.50M).

How large is Logos Global Management LP's portfolio?

Logos Global Management LP reported $1.66B of long equity holdings across 64 positions as of 2026-Q3. Top-10 holdings account for 47.8% of reported value.

What is Logos Global Management LP's investment style?

HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/logos-global-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →